Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618981 | 1.00 | KMT2A (0.46) | KMT2AMAPK1RAB9ANAMPTSCN9A | |
| SCHEMBL27561234 | 0.90 | KMT2A (0.53) | KMT2AMAPK1CTSK | |
| SCHEMBL4712370 | 0.90 | KMT2A (0.53) | KMT2AMAPK1CTSK | |
| SCHEMBL4712368 | 0.90 | KMT2A (0.53) | KMT2AMAPK1CTSK | |
| SCHEMBL5619371 | 0.85 | KMT2A (0.46) | KMT2AMAPK1SCN9AADORA2AADORA2B | |
| SCHEMBL5619366 | 0.85 | KMT2A (0.46) | KMT2AMAPK1SCN9AADORA2AADORA2B | |
| SCHEMBL5618868 | 0.83 | KDM4D (0.41) | NAMPTADORA2AADORA2BCYP3A4CTSK | |
| SCHEMBL5618862 | 0.83 | KDM4D (0.41) | NAMPTADORA2AADORA2BCYP3A4CTSK | |
| SCHEMBL8329117 | 0.83 | KMT2A (0.54) | KMT2AMAPK1CTSK | |
| SCHEMBL8331694 | 0.83 | KMT2A (0.54) | KMT2AMAPK1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427409-A1 | METHODS FOR TREATING OR PREVENTING VASCULAR INFLAMMATION USING STEROL ABSORPTION INHIBITOR(S) | SCHERING CORPORATION (US) | 2004-06-16 | — | — | EP | claimed |
| WO-2003026644-A1 | METHODS FOR TREATING OR PREVENTING VASCULAR INFLAMMATION USING STEROL ABSORPTION INHIBITOR(S) | SCHERING CORPORATION (US) | 2003-04-03 | — | — | WO | claimed |
| US-7186843-B2 | potent antibacterial activity against various bacteria including drug-resistant strains | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2007-03-06 | — | — | US | disclosed |
| US-20040209940-A1 | Aminomethylpyrrolidine derivatives having aromatic substituents | DAIICHI PHARMACEUTICAL CO., LTD. | 2004-10-21 | — | — | US | disclosed |
| US-6762181-B1 | BROAD ANTIBACTERIAL ACTIVITY INCLUDING DRUG RESISTANT STAPHYLOCOCCUS AUREUS (MRSA), PNEUMOCOCCUS (PRSP) AND ENTEROCOCCUS (VRE); SAFELY USED IN CONJUCTION WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-13 | — | — | US | disclosed |
| EP-1429756-A2 | TREATMENT OF XANTHOMA WITH AZETIDINONE DERIVATIVES AS STEROL ABSORPTION INHIBITORS | SCHERING CORPORATION (US) | 2004-06-23 | — | — | EP | disclosed |
| EP-1182202-B1 | AMINOMETHYLPYRROLIDINE DERIVATIVES HAVING AROMATIC SUBSTITUENTS | DAIICHI SEIYAKU CO (JP) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003026643-A2 | TREATMENT OF XANTHOMA WITH AZETIDINONE DERIVATIVES AS STEROL ABSORPTION INHIBITORS | SCHERING CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-1182202-A1 | AMINOMETHYLPYRROLIDINE DERIVATIVES HAVING AROMATIC SUBSTITUENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209940-A1 | Aminomethylpyrrolidine derivatives having aromatic substituents | Q6ZSR9, NAT1, NAT10 | KMT2A 630/4885MAPK1 1910/4885RAB9A 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.